CAGRILINTIDE

Specifications

Molecular Design and Albumin Binding

Native human amylin (islet amyloid polypeptide, IAPP) has a circulating half-life measured in minutes, limiting its utility in sustained-exposure research models. Cagrilintide addresses this through C18 fatty diacid acylation — a lipidation strategy that enables reversible, non-covalent binding to serum albumin. This albumin association creates a circulating depot effect, substantially extending the pharmacokinetic profile compared to unmodified amylin. The approach is conceptually related to the Drug Affinity Complex (DAC) used in CJC-1295, though the underlying chemistry differs. Lau et al. described the design rationale for acylated amylin analogs in the context of sustained receptor engagement (Lau et al., Journal of Medicinal Chemistry, 2015; PubMed 26288685).

Amylin Receptor Pharmacology

The amylin receptor system represents one of the more intricate GPCR signaling networks studied in metabolic research. The three receptor subtypes — AMY1 (CTR + RAMP1), AMY2 (CTR + RAMP2), and AMY3 (CTR + RAMP3) — each exhibit distinct ligand affinity profiles and tissue distribution patterns. Cagrilintide has been investigated for its binding characteristics across all three subtypes. Downstream signaling involves cAMP accumulation through Gαs coupling, with additional contributions from β-arrestin recruitment and receptor internalization pathways (Hay et al., Pharmacological Reviews, 2015; PubMed 26023145). Understanding subtype-selective signaling is a key area of ongoing amylin receptor research.

Published Research and Preclinical Data

Cagrilintide has been examined in multiple preclinical contexts. Lau et al. demonstrated that long-acting amylin analogs produce sustained receptor activation in rodent models, enabling researchers to study the physiological consequences of prolonged amylin signaling rather than the brief, pulsatile exposure that native IAPP provides (PubMed 26288685). Separate investigations have explored cagrilintide in combination with Sema (a GLP-1 receptor agonist), examining the distinct but complementary signaling pathways activated by amylin and GLP-1 receptor engagement in area postrema and hypothalamic circuits (Enebo et al., The Lancet, 2021; PubMed 34004180).

Research Applications

• Amylin receptor subtype (AMY1/2/3) binding selectivity and signaling bias studies
• CTR/RAMP heterodimer formation and modulation research
• Acylated peptide pharmacokinetics — albumin binding dynamics and depot release modeling
• Comparative structure-activity analysis of amylin analogs (pramlintide, native IAPP, cagrilintide)
• Dual-pathway investigation pairing amylin receptor agonism with GLP-1 or GIP receptor activation
• Area postrema and hindbrain neuronal circuit mapping in metabolic signaling models

Frequently Paired With

• SM1 5mg — Enables dual-pathway investigation: amylin signaling through hindbrain circuits alongside GLP-1 receptor engagement through hypothalamic pathways.

Quality and testing

Every Heritage Labs compound is manufactured to research-grade standards and shipped in protective packaging.

Storage

• Lyophilized: Store at -20°C, protected from light and moisture
• Reconstituted: 2-8°C, use within 30 days
• Avoid repeated freeze-thaw cycles

References

1. Lau J, et al. Journal of Medicinal Chemistry. 2015;58(18):7370-7380. PubMed 26288685
2. Hay DL, et al. Pharmacological Reviews. 2015;67(3):564-600. PubMed 26023145
3. Enebo LB, et al. The Lancet. 2021;397(10286):1736-1748. PubMed 34004180

For laboratory research use only. Not for human or veterinary use.